{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:31:58Z","timestamp":1793914318819,"version":"4.8.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T00:00:00Z","timestamp":1749254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T00:00:00Z","timestamp":1749254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the National Key R&D Program of China","award":["2022YFE0133100"],"award-info":[{"award-number":["2022YFE0133100"]}]},{"name":"Natural Science Foundation of Guangdong Province, Chin","award":["2022A1515110399, 2024A1515012860"],"award-info":[{"award-number":["2022A1515110399, 2024A1515012860"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"DOI":"10.1007\/s00330-025-11729-4","type":"journal-article","created":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T13:48:55Z","timestamp":1749304135000},"page":"8105-8115","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Improving prediction of lymph node response to neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer via dynamic [18F]FDG PET\/CT"],"prefix":"10.1007","volume":"35","author":[{"given":"Shaopeng","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haijie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weitao","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihua","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aotian","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weifeng","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rixin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9200-9317","authenticated-orcid":false,"given":"Guibin","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,7]]},"reference":[{"key":"11729_CR1","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1056\/NEJMoa2215530","volume":"389","author":"M Provencio","year":"2023","unstructured":"Provencio M, Nadal E, Gonz\u00e1lez-Larriba JL et al (2023) Perioperative nivolumab and chemotherapy in stage III non-small-cell lung cancer. N Engl J Med 389:504\u2013513","journal-title":"N Engl J Med"},{"key":"11729_CR2","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde PM, Spicer J, Lu S et al (2022) Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med 386:1973\u20131985","journal-title":"N Engl J Med"},{"key":"11729_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107401","volume":"186","author":"S Huang","year":"2023","unstructured":"Huang S, Wu J, Li S et al (2023) Evaluation of combined pathological responses in primary tumor and lymph nodes following neoadjuvant chemoimmunotherapy in non-small cell lung cancer. Lung Cancer 186:107401","journal-title":"Lung Cancer"},{"key":"11729_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005160","volume":"10","author":"WY Zhai","year":"2022","unstructured":"Zhai WY, Zhao ZR, Chen S et al (2022) Response of primary tumor and lymph node in non-small cell lung cancer after neoadjuvant immunotherapy: a pooled analysis. J Immunother Cancer 10:e005160","journal-title":"J Immunother Cancer"},{"key":"11729_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102422","volume":"68","author":"C Sun","year":"2024","unstructured":"Sun C, Wang X, Xu Y et al (2024) Efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy in potentially resectable stage IIIA\/IIIB non-small cell lung cancer: Neo-Pre-IC, a single-arm phase 2 trial. EClinicalMedicine 68:102422","journal-title":"EClinicalMedicine"},{"key":"11729_CR6","doi-asserted-by":"crossref","unstructured":"Kim IH, Lee GD, Choi S et al (2024) Validation study for the N descriptor of the newly proposed ninth edition of the TNM staging system proposed by the International Association for the Study of Lung Cancer. J Thorac Oncol 19:1218\u20131227","DOI":"10.1016\/j.jtho.2024.04.002"},{"key":"11729_CR7","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s00259-018-4109-x","volume":"46","author":"J Kirchner","year":"2019","unstructured":"Kirchner J, Sawicki LM, Nensa F et al (2019) Prospective comparison of (18)F-FDG PET\/MRI and (18)F-FDG PET\/CT for thoracic staging of non-small cell lung cancer. Eur J Nucl Med Mol imaging 46:437\u201345.X3","journal-title":"Eur J Nucl Med Mol imaging"},{"key":"11729_CR8","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1097\/JTO.0b013e31821d4384","volume":"6","author":"YL Lv","year":"2011","unstructured":"Lv YL, Yuan DM, Wang K et al (2011) Diagnostic performance of integrated positron emission tomography\/computed tomography for mediastinal lymph node staging in non-small cell lung cancer: a bivariate systematic review and meta-analysis. J Thorac Oncol 6:1350\u20138.X1","journal-title":"J Thorac Oncol"},{"key":"11729_CR9","doi-asserted-by":"publisher","first-page":"6625","DOI":"10.1007\/s00330-023-09922-4","volume":"33","author":"Y Cheng","year":"2023","unstructured":"Cheng Y, Chen ZY, Huang JJ, Shao D (2023) Efficacy evaluation of neoadjuvant immunotherapy plus chemotherapy for non-small-cell lung cancer: comparison of PET\/CT with postoperative pathology. Eur Radiol 33:6625\u20136635","journal-title":"Eur Radiol"},{"key":"11729_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25188-0","volume":"12","author":"T Cascone","year":"2021","unstructured":"Cascone T, Weissferdt A, Godoy MCB et al (2021) Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer. Nat Commun 12:5045","journal-title":"Nat Commun"},{"key":"11729_CR11","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.canlet.2021.06.028","volume":"520","author":"P Jin","year":"2021","unstructured":"Jin P, Li J, Meng Y et al (2021) PET\/CT metabolic patterns in systemic immune activation: a new perspective on the assessment of immunotherapy response and efficacy. Cancer Lett 520:91\u20139.2","journal-title":"Cancer Lett"},{"key":"11729_CR12","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1016\/j.immuni.2021.08.026","volume":"54","author":"JM Schenkel","year":"2021","unstructured":"Schenkel JM, Herbst RH, Canner D et al (2021) Conventional type I dendritic cells maintain a reservoir of proliferative tumor-antigen specific TCF-1(+) CD8(+) T cells in tumor-draining lymph nodes. Immunity 54:2338\u201353.e6","journal-title":"Immunity"},{"key":"11729_CR13","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abg7836","volume":"6","author":"KA Connolly","year":"2021","unstructured":"Connolly KA, Kuchroo M, Venkat A et al (2021) A reservoir of stem-like CD8(+) T cells in the tumor-draining lymph node preserves the ongoing antitumor immune response. Sci Immunol 6:eabg7836","journal-title":"Sci Immunol"},{"key":"11729_CR14","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1007\/s12149-020-01451-0","volume":"34","author":"B Hu","year":"2020","unstructured":"Hu B, Chen W, Zhang Y, Shi H, Cheng D, Xiu Y (2020) (18)F-FDG maximum standard uptake value predicts PD-L1 expression on tumor cells or tumor-infiltrating immune cells in non-small cell lung cancer. Ann Nucl Med 34:322\u2013328","journal-title":"Ann Nucl Med"},{"key":"11729_CR15","doi-asserted-by":"publisher","first-page":"8564","DOI":"10.1007\/s00330-023-09910-8","volume":"33","author":"L Zhang","year":"2023","unstructured":"Zhang L, Haoran E, Huang J et al (2023) Clinical utility of [(18)F]FDG PET\/CT in the assessment of mediastinal lymph node disease after neoadjuvant chemoimmunotherapy for non-small cell lung cancer. Eur Radiol 33:8564\u20138572","journal-title":"Eur Radiol"},{"key":"11729_CR16","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"},{"key":"11729_CR17","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1097\/JTO.0b013e3181a0d82e","volume":"4","author":"VW Rusch","year":"2009","unstructured":"Rusch VW, Asamura H, Watanabe H, Giroux DJ, Rami-Porta R, Goldstraw P (2009) The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol 4:568\u2013577","journal-title":"J Thorac Oncol"},{"key":"11729_CR18","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1097\/JTO.0b013e3181ec7e70","volume":"5","author":"M Nakao","year":"2010","unstructured":"Nakao M, Yoshida J, Ishii G et al (2010) Prognostic impact of node involvement pattern in pN1 non-small cell lung cancer patients. J Thorac Oncol 5:1576\u20131582","journal-title":"J Thorac Oncol"},{"key":"11729_CR19","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1097\/MNM.0000000000001456","volume":"42","author":"J Hua","year":"2021","unstructured":"Hua J, Li L, Liu L, Liu Q, Liu Y, Chen X (2021) The diagnostic value of metabolic, morphological and heterogeneous parameters of 18F-FDG PET\/CT in mediastinal lymph node metastasis of non-small cell lung cancer. Nucl Med Commun 42:1247\u201353.X2","journal-title":"Nucl Med Commun"},{"key":"11729_CR20","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1111\/imr.12399","volume":"271","author":"G Gasteiger","year":"2016","unstructured":"Gasteiger G, Ataide M, Kastenm\u00fcller W (2016) Lymph node\u2014an organ for T-cell activation and pathogen defense. Immunol Rev 271:200\u2013220","journal-title":"Immunol Rev"},{"key":"11729_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-025-13905-7","volume":"25","author":"X Liu","year":"2025","unstructured":"Liu X, Ji Z, Zhang L, Li L, Xu W, Su Q (2025) Prediction of pathological complete response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer using (18)F-FDG PET radiomics features of primary tumour and lymph nodes. BMC Cancer 25:520","journal-title":"BMC Cancer"},{"key":"11729_CR22","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.jtcvs.2015.09.127","volume":"151","author":"RT Ripley","year":"2016","unstructured":"Ripley RT, Suzuki K, Tan KS et al (2016) Postinduction positron emission tomography assessment of N2 nodes is not associated with ypN2 disease or overall survival in stage IIIA non-small cell lung cancer. J Thorac Cardiovasc Surg 151:969\u2013977. 79.e1-3","journal-title":"J Thorac Cardiovasc Surg"},{"key":"11729_CR23","doi-asserted-by":"publisher","first-page":"e241285","DOI":"10.1001\/jamanetworkopen.2024.1285","volume":"7","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Li A, Yu H et al (2024) Neoadjuvant-adjuvant vs neoadjuvant-only PD-1 and PD-L1 inhibitors for patients with resectable NSCLC: an indirect meta-analysis. JAMA Netw open 7:e241285","journal-title":"JAMA Netw open"},{"key":"11729_CR24","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s13402-023-00873-y","volume":"47","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Li L, Gao Y et al (2024) Immune characteristics associated with lymph node metastasis in early-stage NSCLC. Cell Oncol 47:447\u2013461","journal-title":"Cell Oncol"},{"key":"11729_CR25","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.cell.2023.02.021","volume":"186","author":"MK Rahim","year":"2023","unstructured":"Rahim MK, Okholm TLH, Jones KB et al (2023) Dynamic CD8(+) T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes. Cell 186:1127\u201343.e18.LN8","journal-title":"Cell"},{"key":"11729_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.643291","volume":"12","author":"KM van Pul","year":"2021","unstructured":"van Pul KM, Fransen MF, van de Ven R, de Gruijl TD (2021) Immunotherapy goes local: the central role of lymph nodes in driving tumor infiltration and efficacy. Front Immunol 12:643291","journal-title":"Front Immunol"},{"key":"11729_CR27","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/s41423-021-00792-8","volume":"19","author":"JM Marchingo","year":"2022","unstructured":"Marchingo JM, Cantrell DA (2022) Protein synthesis, degradation, and energy metabolism in T cell immunity. Cell Mol Immunol 19:303\u2013315","journal-title":"Cell Mol Immunol"},{"key":"11729_CR28","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1097\/JS9.0000000000000774","volume":"110","author":"H Deng","year":"2024","unstructured":"Deng H, Zhou J, Chen H et al (2024) Impact of lymphadenectomy extent on immunotherapy efficacy in postresectional recurred non-small cell lung cancer: a multi-institutional retrospective cohort study. Int J Surg 110:238\u2013252","journal-title":"Int J Surg"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-025-11729-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-025-11729-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-025-11729-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T11:44:46Z","timestamp":1763639086000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-025-11729-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,7]]},"references-count":28,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["11729"],"URL":"https:\/\/doi.org\/10.1007\/s00330-025-11729-4","relation":{},"ISSN":["1432-1084"],"issn-type":[{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,7]]},"assertion":[{"value":"20 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The scientific guarantor of this publication is Guibin Qiao.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"One of the authors has significant statistical expertise.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Written informed consent was waived by the Institutional Review Board, because of the retrospective and anonymized nature of the study design.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Institutional Review Board approval was obtained. The study protocol was approved by the Research Ethics Committee of Guangdong Provincial People\u2019s Hospital (no. GDREC2019687H).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Of the 86 patients enrolled in this study, 21 have been previously reported in the article by Huang et al (2023) published in\n                      Lung Cancer\n                      (\n                      \n                      ). The previous study focused on evaluating combined pathological responses in primary tumors and LN following neoadjuvant chemoimmunotherapy in NSCLC. In contrast, this current study investigates the predictive value of dynamic changes in imaging features using [\n                      18\n                      F]FDG PET\/CT to predict lymph node response to neoadjuvant chemoimmunotherapy. Despite the overlap, the studies focus on different aspects and study designs related to NSCLC treatment responses.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study subjects or cohorts overlap"}},{"order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}